drugset / Trial / NCT00142831

Bupropion as an Adjunct to the Nicotine Patch Plus CBT

NCT00142831

Phase 4 Completed 293 enrolled National Institute on Drug Abuse (NIDA)
RandomizedParallel-groupDouble-blindTreatment

Summary

Existing and new pharmacotherapies along with prevention efforts are key to improving smoking cessation rates and reducing the premature morbidity and mortality associated with tobacco use. A number of individuals suffer from both nicotine dependence and depression. The purpose of this study is to determine the effectiveness of bupropion used in combination with the nicotine replacement patch and cognitive behavior therapy (CBT) in treating nicotine dependent individuals also diagnosed with depression.

Timeline

Start
1999-04
Primary completion
2006-08
Completion
2006-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Bupropion Small molecule 300 mg

Indications